Patent · US Active

Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases

US9006237B2 · kind B2 · utility

0Cited by

6References

62Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Martin James Inglis Andrews · Mechelen, BE
Mark Stuart Chambers · Watford, GB
Wolfgang Schmidt · Frankfurt, DE
Giovanni Alessandro Tricarico · Mechelen, BE
Gregory Bar · Mechelen, BE
Kim Louise Hirst · Saffron Walden, GB
Olga Raquel Pinto Santos Oliveira Roussel · Saffron Walden, GB
Juha Andrew Clase · Chapel-en-le-Frith, GB

Key dates

Filing date	Mar 2, 2012
Grant date	Apr 14, 2015
Priority date	—
Expiry date	Oct 6, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel fused pyrazine compounds are disclosed that have a formula represented by the following:The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.